Sunday, November 3, 2013

Merck's 'breakthrough' hep C combo plays catch-up

 Investment Commentary

Merck's 'breakthrough' hep C combo plays catch-up with promising PhII results

November 3, 2013 | By

Merck may be playing catch-up in the race to develop the first all-oral combo treatment for hepatitis C, but it made a good case over the weekend that it has a real contender in the pipeline.
Now its combination of MK-5172, an NS3/4A protease inhibitor, and the NS5A treatment MK-8742 produced cure rates ranging from 96% to 100% among small groups of genotype 1a and 1b patients. A total of 58 evaluable patients were included in the readout with the combo provided both with and without ribavirin.

Read more.....

AASLD-High cure rates seen with Merck oral hepatitis drugs -study

No comments:

Post a Comment